{"name":"Neurology Group of Bergen County, P.A.","slug":"neurology-group-of-bergen-county-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Guanfacine (sustained release)","genericName":"Guanfacine (sustained release)","slug":"guanfacine-sustained-release","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents","status":"marketed"}]}],"pipeline":[{"name":"Guanfacine (sustained release)","genericName":"Guanfacine (sustained release)","slug":"guanfacine-sustained-release","phase":"marketed","mechanism":"Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine activity in the prefrontal cortex to improve attention and impulse control.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents","Hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}